Trastuzumab, a recombinant humanised monoclonal antibody of the IgG1 isotype, which recognises the HER2 receptor overexpressed on some breast cancers, has been shown to improve survival rates in patients with early-stage HER2-positive breast cancer [9]. The gene discussed is ERBB2; the disease is breast cancer.